<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370301</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006957</org_study_id>
    <secondary_id>NCI-2020-02422</secondary_id>
    <secondary_id>RG1006957</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04370301</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis</brief_title>
  <official_title>Pilot Study of Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the outcomes of using a JAK inhibitor prior to reduced intensity
      haploidentical (Haplo) transplantation for the treatment of primary or secondary
      myelofibrosis (MF). Haplo transplant has been shown to be safe and effective in patients with
      leukemia and lymphoma who don't have an available sibling donor. The primary risk of using
      Haplo HCT in patients with MF is graft failure as the graft failure rate has been
      historically higher with Haplo HCT than with other donor sources and higher with MF patients
      due to bone marrow fibrosis than in patients with other hematologic malignancies. JAK
      inhibitors when used in patients with MF may decrease the size of the spleen and decrease
      inflammation in the bone marrow. Therefore using a JAK inhibitor prior to Haplo transplant
      has the potential to decrease graft failure in patients with MF. Haplo transplants for
      patients with MF have been done successfully at multiple institutions in patients not on a
      study and are currently being covered by Medicare.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

      JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start
      of hematopoietic cell transplantation (HCT) conditioning through day -4 before
      transplantation.

      CONDITIONING: Patients receive melphalan intravenously (IV) over 1 hour on day -5,
      fludarabine IV over 30-60 minutes on days -5 to -2, and undergo total-body irradiation (TBI)
      on day -1.

      TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.

      GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4,
      tacrolimus IV beginning day 5 then orally (PO) for 6 months, mycophenolate mofetil PO twice
      daily (BID) or three times daily (TID) beginning day 5 for 6 weeks, and granulocyte
      colony-stimulating factor (G-CSF) subcutaneously (SC) beginning day 7 until neutrophil
      recovery is &gt; 1,500/mm^3.

      After completion of study treatment, patients are followed up between day 80-100, at 1 year,
      and then up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of primary and secondary graft failure</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe (grade 3 or 4) cytokine release syndrome</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic graft versus host disease (GVHD)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JAK INHIBITOR THERAPY: Patients receive a JAK inhibitor at least 8 weeks prior to the start of HCT conditioning through day -4 before transplantation.
CONDITIONING: Patients receive melphalan IV over 1 hour on day -5, fludarabine IV over 30-60 minutes on days -5 to -2, and undergo TBI on day -1.
TRANSPLANT: Patients receive peripheral blood stem cell infusion on day 0.
GVHD PROPHYLAXIS: Patients then receive cyclophosphamide IV over 3 hours on days 3-4, tacrolimus IV beginning day 5 then PO for 6 months, mycophenolate mofetil PO BID or TID beginning day 5 for 6 weeks, and G-CSF SC beginning day 7 until neutrophil recovery is &gt; 1,500/mm^3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JAK Inhibitor</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Ruxolitinib</other_name>
    <other_name>Fedratinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte Colony-Stimulating Factor</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Colony Stimulating Factor 3</other_name>
    <other_name>Colony-Stimulating Factor (Granulocyte)</other_name>
    <other_name>Colony-Stimulating Factor 3</other_name>
    <other_name>CSF3</other_name>
    <other_name>G CSF</other_name>
    <other_name>G-CSF</other_name>
    <other_name>Granulocyte Colony Stimulating Factor</other_name>
    <other_name>Pluripoietin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine mustard</other_name>
    <other_name>L-sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Blood Stem Cell Transplantation</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>PBPC transplantation</other_name>
    <other_name>PBSCT</other_name>
    <other_name>Peripheral Blood Progenitor Cell Transplantation</other_name>
    <other_name>peripheral stem cell support</other_name>
    <other_name>Peripheral Stem Cell Transplant</other_name>
    <other_name>peripheral stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (JAK inhibitor, conditioning, GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PART 1: JAK INHIBITOR ADMINISTRATION INCLUSION CRITERIA

          -  Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health
             Organization classification system or diagnosis of secondary MF as defined by the
             International Working Group (IWG) for Myeloproliferative Neoplasms Research and
             Treatment criteria

          -  Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk disease
             by the Dynamic International Prognostic Scoring System (DIPSS)-plus scoring system
             (DIPSS may be used if all data from DIPSS are not available)

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patient must be a potential hematopoietic stem cell transplant candidate

          -  PART 2: ALLOGENEIC STEM CELL TRANSPLANT INCLUSION CRITERIA

          -  Meeting criteria for 1st phase as above, at time of initiation of JAK inhibitor,
             including ability to understand and willingness to sign a written informed consent.
             Patients arriving to our institution for transplant and not enrolled in Part 1 may
             still be enrolled in Part 2 if Part 1 criteria met. These patients will have Part 1
             endpoints transcribed from medical records

          -  Received JAK inhibitor for at least 8 weeks immediately prior to conditioning and be
             able to continue until day -4 pre-transplant

          -  Karnofsky performance status score &gt;= 70

          -  Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr)
             urine creatinine clearance must be &gt; 60 ml/min

          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to
             Gilbert's disease or hemolysis

          -  Transaminases must be &lt; 3 x the upper limit of normal

          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for
             the cause of liver disease, its clinical severity in terms of liver function, and the
             degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with
             evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic
             encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation
             of the prothrombin time, ascites related to portal hypertension, bacterial or fungal
             abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin &gt; 3
             mg/dL, and symptomatic biliary disease will be excluded

          -  Diffusion capacity of the lung for carbon monoxide (DLCO) corrected &gt; 60% normal; may
             not be on supplemental oxygen

          -  Left ventricular ejection fraction &gt; 40% OR shortening fraction &gt; 26%

          -  Comorbidity Index &lt; 5 at the time of pre-transplant evaluation

          -  DONOR: Patients must be screened prior to transplant for donor-specific anti-HLA
             antibodies (DSA). Patients with DSA will be reviewed by the principal investigator and
             considered for desensitization treatment

          -  DONOR: Children are preferred over siblings and parents

          -  DONOR: Younger donors are preferred over older donors

          -  DONOR: ABO matched donors are preferred over minor ABO mismatched and over major ABO
             mismatch donors

        Exclusion Criteria:

          -  PART 1: JAK INHIBITOR ADMINISTRATION EXCLUSION CRITERIA

          -  Contraindication to receiving a JAK inhibitor including:

               -  Patients who have known hypersensitivity to JAK inhibitors

               -  Clinical or laboratory evidence of significant renal or hepatic impairment
                  including cirrhosis

               -  Active uncontrolled infection

               -  Known human immunodeficiency virus (HIV) positivity

               -  Women who are pregnant or trying to conceive

               -  Caution should be used in patients with platelets &lt; 100 though adjustments in
                  dose can be made to accommodate anyone with platelets &gt; 50

          -  History of prior allogeneic transplant

          -  Leukemic transformation (&gt; 20% blasts)

          -  PART 2: ALLOGENEIC STEM CELL TRANSPLANT EXCLUSION CRITERIA

          -  Uncontrolled viral or bacterial infection at the time of study enrollment

          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease
             (ID) consult and approval

          -  Known HIV positivity

          -  Pregnant or breastfeeding

          -  Availability of an human leukocyte antigen (HLA)-identical or 1-allele-mismatched
             related donor or an HLA 10 of 10 matched unrelated donor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel B Salit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel Salit</last_name>
    <phone>206-667-1317</phone>
    <email>rsalit@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel B. Salit</last_name>
      <phone>206-667-1317</phone>
      <email>rsalit@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Rachel B. Salit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Janus Kinase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

